Comparison of the effects of two marketed calcium preparations on reducing serum markers of bone resorption in post menopausal women
Comparison of the effects of two marketed Calcium preparations on reducing serum markers of bone resorption in post menopausal women
Institute of Medical and Veterinary Science, Frome road, Adelaide, SA 5000
25 participants
Nov 1, 2006
Interventional
Conditions
Summary
Calcium supplementation has been shown to reduce the incidence of osteoporosis and related fractures. Currently Calsup (calcium carbonate) is marketed widely in Australia. This study is to compare the effects of Calsup with a newer calcium supplement, Citracal (Calcium citrate) on reducing serum markers of bone resorption. The hypothesis is that citracal may be equally effective in smaller doses and would have less side effects.
Eligibility
Inclusion Criteria1
- Post menopausal (menopause within last 5 years)
Exclusion Criteria1
- renal failure, intake of calcium supplements, hypercalcaemiaany bone disorder.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
A cross over trial using Calsup (calcium carbonate) 1000 mg and Citracal (calcium citrate) 500mg given as single doses orally, one week apart following base line serum tests.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12606000458538